Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

altRX vs Claya

altRX
Graded #92

Higher grade

vs+8.600000000000009
Claya
Graded #267

Lower grade

The verdict

altRX takes it — 71.4/100 to 62.8/100.

altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuealtRX +32
74
42
Dose & formulationaltRX +2
77
75
Clinical oversightEven
82
82
Labs & monitoringEven
53
53
FulfillmentaltRX +6
73
67
Contract termsClaya +6
55
61
altRX · left barClaya · right bar

The numbers

MetricaltRXClaya
WeighScore71.4/10062.8/100
GradeCC
Scorecard rank#92#267
Semaglutide$149/mo (starting dose, compounded)$299/mo (compounded)
Tirzepatide$249/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
altRX

Graded #92 · C

Strengths

  • Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
  • LegitScript Certified with a publicly verifiable seal
  • Publishes the FDA compounded-medication disclaimer
  • Transparent pricing across all six product tiers (compounded plus four brand-name)
  • All-inclusive pricing — consult, prescription, and shipping with no hidden fees

Where it loses points

  • States-served list not disclosed
  • 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
  • 503A vs 503B designation not specified
  • No named medical director
  • Corporate physical address not disclosed
Claya

Graded #267 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard